ArticleAvicenna journal of phytomedicine
Comparison
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The effects of Materials and Methods: This clinical trial took place in Gorgan, Iran with 70 diabetic nephropathy patients who had hypertension. The participants were divided into two groups: The HSE group which received 500 mg HSE along with valsartan 40 mg twice daily over three months (n=35) and the control group which received valsartan plus hydrochlorothiazide 12.5 mg (n=35). The study measured blood pressure levels with additional assessments of microalbuminuria, proteinuria, and glomerular filtration rate (GFR) alongside lipid profile analysis, and hemoglobin A1c (HbA1c), fasting blood glucose (FBS), and electrolyte tests. Molecular docking simulations tested HSE compounds as potential inhibitors of sodium-glucose cotransporter-2 (SGLT2), dipeptidyl peptidase-4 (DPP-4), glucagon-like peptide-1 (GLP-1), and Receptor for advanced glycation end products (RAGE). Results: Both groups showed improvements, but HSE had a greater impact on kidney function and lipid levels, while control group was more effective in lowering blood pressure and improving glucose metabolism. Docking analysis revealed that cyanidin 3-O-beta-D-sambubioside and tiliroside strongly interacted with targets, suggesting a role in blood glucose regulation and insulin secretion. Conclusion: HSE demonstrates the potential to help type 2 diabetic nephropathy patients by modifying renin-angiotensin-aldosterone system activity carbohydrate digestion processes and lipid metabolism which reduces diabetic complications risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.